EXPRESSION OF ANGPTL5 AND MYBL2 IN GASTRIC CANCER AND THEIR CORRELATION WITH CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS

Meirui Qian1,#, Chen Zhang**,#, Nan He*

* National Translational Science Center for Molecular Medicine & Department of Cell Biology, The Fourth Military Medical University, Xi'an, China, 710032 - **Department of Orthopaedics, Xijing Hospital, Air Force Medical University, Xi’an, PR China

Objective: To investigate the expression of ANGPTL5 and MYBL2 in gastric cancer and their correlation with clinicopathological features and prognosis.

Methods: A total of 74 paraffin specimens of cancer tissue and normal paracancerous tissue were collected from gastric cancer patients who underwent radical operation in our hospital between August 2018 and February 2019. The expression of ANGPTL5 and MYBL2 in gastric cancer tissues and normal paracancerous tissues, the relationship between the expression of ANGPTL5, MYBL2 and clinicopathological data of gastric cancer patients, and the relationship between ANGPTL5 and MYBL2 expression in gastric cancer tissues and the overall survival time of patients was compared by immunohistochemistry methods.

Results: The positive expression rate of ANGPTL5 in gastric cancer tissues was 66.86%, which was significantly higher than that in paracancerous tissues, by 16.18% (P<0.05). The positive expression rate of MYBL2 in gastric cancer tissues was 62.51%, which was obviously higher than that in paracancerous tissues, by 13.65% (P<0.05). The expression of ANGPTL5 in gastric cancer tissues was correlated with tumour size and depth of invasion (P<0.05) but not with age or lymph node metastasis (P>0.05). The expression of MYBL2 in gastric cancer tissues was correlated with histologic type, depth of invasion and lymph node metastasis (P<0.05) but not with age (P>0.05). The log–rank test showed that the 5-year survival rate of ANGPTL5-positive patients was 18.37% (9/49), which was significantly lower than that of ANGPTL5-negative patients (44.00%, 11/25) (P<0.05). The 5-year survival rate of MYBL2-positive patients was 30.0322.64% (12/53), which was significantly lower than that of MYBL2-negative patients (38.10%, 8/21) (P<0.05). The depth of tumour infiltration, presence or absence of lymph node metastasis and expression levels of ANGPTL5 and MYBL2 were used as independent risk factors affecting the prognosis of patients with gastric cancer in this group. 

Conclusion: The overexpression of ANGPTL5 and MYBL2 in gastric cancer is closely related to the size of primary tumour, depth of invasion and a poor prognosis, which indicates that ANGPTL5 and MYBL2 may be involved in the occurrence and development of gastric cancer.